Its good to see our directors have their finger on the pulse
Reading the last couple of paragraphs in todays announcements it seems to me like the company has official proof that the market size for Artimist has meaningfully increased, and have armed themselves with this information to enter into sale negotiations.
So we now have a company who has completed a Phase III trial with a market cap of under $15m. Pocket change for any one of the global pharma players.
EMS Price at posting:
2.4¢ Sentiment: None Disclosure: Held
